Health-state utilities in liver disease

A systematic review

David John McLernon, J. F. Dillon, P. T. Donnan

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Objectives. Health-state utilities are essential for cost-utility analysis. Few estimates exist for liver disease in the literature. The authors' aim was to conduct a systematic review of health-state utilities in liver disease, to look at the variation of study designs used, and to pool utilities for some liver disease states. Methods. A search of MED-LINE, EMBASE, and CINAHL from 1966 to September 2006 was conducted including key words related to liver disease and utility measuring tools. Articles were included if health-state utility tools or expert opinion were used. Variance-weighted mean utility estimates were pooled using metaregression adjusting for disease state and utility assessment method. Results. Thirty studies measured utilities of liver diseases/disease states. Half of these estimated utilities for hepatitis viruses: hepatitis A (n = 1), hepatitis B (n = 4), and hepatitis C (n = 10). Others included liver transplant (n= 6) and chronic liver disease (n= 5) populations. Twelve utility methods were used throughout. The EQ-5D (n = 10) was most popular method, followed by visual analogue scale (n = 9), time tradeoff (n = 6), and standard gamble (n = 4). Respondents were patients (n= 16), an expert panel (n = 10), non—liver diseases adults ( n=2), patient and expert (n = 1), and patient and healthy adult (n = 1). Type of perspective included community (n=21), patient (n=4), and both (n = 5). The pooled mean estimates in hepatitis C with moderate disease, compensated cirrhosis, decompensated cirrhosis, and post—liver transplant using the EQ-5D were 0.75, 0.75, 0.67, and 0.71, respectively. The change in these utilities using different methods were -0.07 (visual analogue scale), -0.01 (health utilities index version 3), +0.04 (standard gamble), + 0.08 (health utilities index version 2), + 0.12 (time tradeoff), and + 0.15 (standard gamble—transformed visual analogue scale). Conclusions. The authors have created a valuable liver disease— based utility resource from which researchers and policy makers can easily view all available utility estimates from the literature. They have also estimated health-state utilities for major states of hepatitis C.
Original languageEnglish
Pages (from-to)582-592
Number of pages11
JournalMedical Decision Making
Volume28
Issue number4
Early online date18 Apr 2008
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Liver Diseases
Health
Hepatitis C
Visual Analog Scale
Fibrosis
Transplants
Hepatitis Viruses
Hepatitis A
Expert Testimony
Administrative Personnel
Hepatitis B
Cost-Benefit Analysis
Chronic Disease
Research Personnel
Liver
Population

Keywords

  • health-state utility
  • liver disease
  • systematic review
  • meta-analysis
  • hepatitis-C
  • quality of life
  • chronic hepatitis-C
  • cost effectiveness
  • economic appraisal
  • preference
  • interferon alpha-2B
  • transplantation
  • infection cirrhosis

Cite this

Health-state utilities in liver disease : A systematic review. / McLernon, David John; Dillon, J. F.; Donnan, P. T.

In: Medical Decision Making, Vol. 28, No. 4, 07.2008, p. 582-592.

Research output: Contribution to journalArticle

McLernon, David John ; Dillon, J. F. ; Donnan, P. T. / Health-state utilities in liver disease : A systematic review. In: Medical Decision Making. 2008 ; Vol. 28, No. 4. pp. 582-592.
@article{27607da7d9bb433ea10ee7ddb79a06f4,
title = "Health-state utilities in liver disease: A systematic review",
abstract = "Objectives. Health-state utilities are essential for cost-utility analysis. Few estimates exist for liver disease in the literature. The authors' aim was to conduct a systematic review of health-state utilities in liver disease, to look at the variation of study designs used, and to pool utilities for some liver disease states. Methods. A search of MED-LINE, EMBASE, and CINAHL from 1966 to September 2006 was conducted including key words related to liver disease and utility measuring tools. Articles were included if health-state utility tools or expert opinion were used. Variance-weighted mean utility estimates were pooled using metaregression adjusting for disease state and utility assessment method. Results. Thirty studies measured utilities of liver diseases/disease states. Half of these estimated utilities for hepatitis viruses: hepatitis A (n = 1), hepatitis B (n = 4), and hepatitis C (n = 10). Others included liver transplant (n= 6) and chronic liver disease (n= 5) populations. Twelve utility methods were used throughout. The EQ-5D (n = 10) was most popular method, followed by visual analogue scale (n = 9), time tradeoff (n = 6), and standard gamble (n = 4). Respondents were patients (n= 16), an expert panel (n = 10), non—liver diseases adults ( n=2), patient and expert (n = 1), and patient and healthy adult (n = 1). Type of perspective included community (n=21), patient (n=4), and both (n = 5). The pooled mean estimates in hepatitis C with moderate disease, compensated cirrhosis, decompensated cirrhosis, and post—liver transplant using the EQ-5D were 0.75, 0.75, 0.67, and 0.71, respectively. The change in these utilities using different methods were -0.07 (visual analogue scale), -0.01 (health utilities index version 3), +0.04 (standard gamble), + 0.08 (health utilities index version 2), + 0.12 (time tradeoff), and + 0.15 (standard gamble—transformed visual analogue scale). Conclusions. The authors have created a valuable liver disease— based utility resource from which researchers and policy makers can easily view all available utility estimates from the literature. They have also estimated health-state utilities for major states of hepatitis C.",
keywords = "health-state utility, liver disease, systematic review, meta-analysis, hepatitis-C, quality of life, chronic hepatitis-C, cost effectiveness, economic appraisal, preference, interferon alpha-2B, transplantation, infection cirrhosis",
author = "McLernon, {David John} and Dillon, {J. F.} and Donnan, {P. T.}",
year = "2008",
month = "7",
doi = "10.1177/0272989x08315240",
language = "English",
volume = "28",
pages = "582--592",
journal = "Medical Decision Making",
issn = "0272-989X",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Health-state utilities in liver disease

T2 - A systematic review

AU - McLernon, David John

AU - Dillon, J. F.

AU - Donnan, P. T.

PY - 2008/7

Y1 - 2008/7

N2 - Objectives. Health-state utilities are essential for cost-utility analysis. Few estimates exist for liver disease in the literature. The authors' aim was to conduct a systematic review of health-state utilities in liver disease, to look at the variation of study designs used, and to pool utilities for some liver disease states. Methods. A search of MED-LINE, EMBASE, and CINAHL from 1966 to September 2006 was conducted including key words related to liver disease and utility measuring tools. Articles were included if health-state utility tools or expert opinion were used. Variance-weighted mean utility estimates were pooled using metaregression adjusting for disease state and utility assessment method. Results. Thirty studies measured utilities of liver diseases/disease states. Half of these estimated utilities for hepatitis viruses: hepatitis A (n = 1), hepatitis B (n = 4), and hepatitis C (n = 10). Others included liver transplant (n= 6) and chronic liver disease (n= 5) populations. Twelve utility methods were used throughout. The EQ-5D (n = 10) was most popular method, followed by visual analogue scale (n = 9), time tradeoff (n = 6), and standard gamble (n = 4). Respondents were patients (n= 16), an expert panel (n = 10), non—liver diseases adults ( n=2), patient and expert (n = 1), and patient and healthy adult (n = 1). Type of perspective included community (n=21), patient (n=4), and both (n = 5). The pooled mean estimates in hepatitis C with moderate disease, compensated cirrhosis, decompensated cirrhosis, and post—liver transplant using the EQ-5D were 0.75, 0.75, 0.67, and 0.71, respectively. The change in these utilities using different methods were -0.07 (visual analogue scale), -0.01 (health utilities index version 3), +0.04 (standard gamble), + 0.08 (health utilities index version 2), + 0.12 (time tradeoff), and + 0.15 (standard gamble—transformed visual analogue scale). Conclusions. The authors have created a valuable liver disease— based utility resource from which researchers and policy makers can easily view all available utility estimates from the literature. They have also estimated health-state utilities for major states of hepatitis C.

AB - Objectives. Health-state utilities are essential for cost-utility analysis. Few estimates exist for liver disease in the literature. The authors' aim was to conduct a systematic review of health-state utilities in liver disease, to look at the variation of study designs used, and to pool utilities for some liver disease states. Methods. A search of MED-LINE, EMBASE, and CINAHL from 1966 to September 2006 was conducted including key words related to liver disease and utility measuring tools. Articles were included if health-state utility tools or expert opinion were used. Variance-weighted mean utility estimates were pooled using metaregression adjusting for disease state and utility assessment method. Results. Thirty studies measured utilities of liver diseases/disease states. Half of these estimated utilities for hepatitis viruses: hepatitis A (n = 1), hepatitis B (n = 4), and hepatitis C (n = 10). Others included liver transplant (n= 6) and chronic liver disease (n= 5) populations. Twelve utility methods were used throughout. The EQ-5D (n = 10) was most popular method, followed by visual analogue scale (n = 9), time tradeoff (n = 6), and standard gamble (n = 4). Respondents were patients (n= 16), an expert panel (n = 10), non—liver diseases adults ( n=2), patient and expert (n = 1), and patient and healthy adult (n = 1). Type of perspective included community (n=21), patient (n=4), and both (n = 5). The pooled mean estimates in hepatitis C with moderate disease, compensated cirrhosis, decompensated cirrhosis, and post—liver transplant using the EQ-5D were 0.75, 0.75, 0.67, and 0.71, respectively. The change in these utilities using different methods were -0.07 (visual analogue scale), -0.01 (health utilities index version 3), +0.04 (standard gamble), + 0.08 (health utilities index version 2), + 0.12 (time tradeoff), and + 0.15 (standard gamble—transformed visual analogue scale). Conclusions. The authors have created a valuable liver disease— based utility resource from which researchers and policy makers can easily view all available utility estimates from the literature. They have also estimated health-state utilities for major states of hepatitis C.

KW - health-state utility

KW - liver disease

KW - systematic review

KW - meta-analysis

KW - hepatitis-C

KW - quality of life

KW - chronic hepatitis-C

KW - cost effectiveness

KW - economic appraisal

KW - preference

KW - interferon alpha-2B

KW - transplantation

KW - infection cirrhosis

U2 - 10.1177/0272989x08315240

DO - 10.1177/0272989x08315240

M3 - Article

VL - 28

SP - 582

EP - 592

JO - Medical Decision Making

JF - Medical Decision Making

SN - 0272-989X

IS - 4

ER -